Publications by Dipen J. Parekh, M.D.

17. Books:


18. Juried or Refereed Journal Articles:


17. Parekh, DJ. Commentary on early hormonal therapy for PSA only recurrence after radical prostatectomy—success towards survival or antidote to anxiety? J. Urol 2008;179(5supp)


44. Koch MO, Bell B, Foster R, Bihrle R, Wahle G, Parekh DJ, Jung SH. Predictors of rapid PSA progression after radical prostatectomy in TxNo adenocarcinoma of the prostate Journal of Urology Jan;164(3 Pt 1):749-753

19. Other Works, Publications & Abstracts:


3. Lowrance WT, Parekh DJ. The rapid uptake of robotic prostatectomy and its collateral effects. Cancer 2011 Jun


6. Parekh DJ, Ankerst DP, Thompson IM. Prostate-specific antigen levels, prostate-specific antigen kinetics, and
20. Other works accepted for publication:

PROFESSIONAL

21. Funded Research

Federal

**Principal Investigator.** Funded by NIH-NCI: RO1
Title: CA155388-01A1 Open versus Robot assisted radical cystectomy: A randomized trial. Total costs: $3,027,389.00.
Grant Detail: The research project entails a multi-institutional prospective randomized clinical trial comparing open versus robotic assisted radical cystectomy for the treatment of bladder cancer.

Co-Investigator. Funded by NIH/NCI.
Title: 1RO1 CA 138627-01A 2. Total costs: $2,205,182.00.
Grant Detail: Improving prostate biopsy efficiency: The finasteride challenge test. A prospective, randomized, placebo-controlled study in a multi-racial group of men who are having prostate biopsy.

Private

Co-Investigator. Funded by Adolor Corporation.
Project #: 14C:403: Title: A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy. Total costs: $120,000.00. Grant Detail: The primary objective of this study is to demonstrate that alvimopan accelerates recovery of gastrointestinal (GI) function in subjects undergoing radical cystectomy. The secondary objectives are to demonstrate that alvimopan on prespecified postoperative ileus (POI)-related morbidities in subjects undergoing radical cystectomy; to evaluate the overall and cardiovascular (CV) safety of alvimopan in subjects undergoing radical cystectomy using an independently adjudicated safety database; to evaluate the primary resource use patterns and medical costs in subjects undergoing radical cystectomy.

**Principal Investigator.** Funded by William and Ella Owens Medical Research Foundation. Title: William and Ella Owens Medical Research Foundation. Total costs: $20,000.00. Grant detail: This grant supports generating preliminary data for a prospective randomized trial comparing open versus robotic radical cystectomy for bladder cancer.

**Principal Investigator.** Funded by The Rotary International Ambassadorial Scholarship. Title: The Rotary International Ambassadorial Scholarship $25,000 for conducting research in Urologic Oncology in Vanderbilt.
University Medical Center

State

Co-Investigator. Funded by CPRIT. Project #: RP101382. Title: 09/2010 – 08/2013 RP101382. Total costs: $285,000.00. Grant detail: Texas Cancer Diagnostics Pipeline Consortium. An innovative technology platform that spans the largest analytic diversity to date for a point-of-care test system, with a Texas-based commercial partner positioned to launch the first product based on the NBC approach, the biomarker highway approach has been successfully vetted with an HIV monitoring humanitarian application scheduled to reach clinical practice in 2010. This program will develop devices that are cost-effective for cancer screening and diagnostic testing procedures. These devices are projected to lead to major improvements in cancer management.

Principal Investigator. Funded by UTHSCSA. Title: Southern Texas Multidisciplinary Clinical Research grant. Total costs: $200,000.00. Grant detail: Biomarkers in prostate cancer and risk based detection of prostate cancer. Response of kidneys to renal ischemia.

Patents:

Category: Biological. Pending, Patent # 61/367,252, Co-Inventor(s) Yusheng Feng, Justin Long, Luis Davila 11/2010

22. Editorial responsibilities:

Editorial Board Member. Type: National. Description: Pathobiology of Human Disease 07/2011 – Present

Editor. Type: International. Description: Assistant Editor 01/2011 – 12/2014

Reviewer. Type: International. Description: Journal of Endourology 01/2010 – Present

Reviewer. Type: International. Description: Cancer 01/2009 – Present


Reviewer. Type: International. Description: Biomarkers in Medicine 03/2007 – Present

Reviewer. Type: International. Description: Urology 01/2007 – Present

Reviewer. Type: International. Description: Indian Journal of Urology 01/2007 – Present

23. **Professional and Honorary Organizations:**

- Bexar County Medical Society 06/2009 – Present
- Society of Urologic Oncology 05/2008 – Present
- South Central Section, AUA 03/2008 – Present
- South West Oncology Group SWOG 07/2007 – Present
- Texas Urology Society 07/2007 – Present
- Vanderbilt Urology Society 10/2004 – Present
- Society of Endourology 01/2004 – Present
- American Urological Association 07/2000 – Present
- Southeastern Section, AUA 07/2000 – Present
- Mumbai Urology Society, India 07/1995 – Present
- Urology Society of India 07/1995 – Present

**Committees (UTHSCSA Standing Committees):**

- Review Committee: Clinical and Translational Science Award Committee 01/2012 – Present
- Supervising Committee: GU Oncology Biorepository, UTHSCSA, Urology/Pathology 01/2010 - Present
- Representative: Professional Liability Subcommittee, UTHSCSA, Medical, Urology 06/2009 - Present

**Committees (Other):**

- Representative: GU Representative, Surgical Committee, Southwest Oncology Group 02/2009 – Present
- Member: Surgery Committee, Southwest Oncology Group 02/2009 – Present
Member: Abstract Review Committee – Robotics, Laparoscopy and New Technology AUA Annual Meeting 12/2008 - Present

Member: Localized Prostate Cancer Guidelines Committee, American Urological Association 05/2007 - Present

24. Honors and Awards:

SWOG Young Investigators, Sept, 2009

Doctors Hospital at Renaissance Distinguished University Chair in Urology: 2 million dollar endowed chair awarded to the Department of Urology by Doctors Hospital Renaissance, McAllen, Texas. Dr. Parekh is the first holder of the endowed chair, 2009

Journal of Urology Most Outstanding Reviewer Award, 2008, 2009

Pfizer Scholar in Urology, 2005


Pfizer Scholar in Urology, 2004

International Volunteers in Urology Resident Scholar, 2002

Honorable Mention: Highlight Session of the American Urological Association, Orlando, FL. Orthotopic neobladder following radical cystectomy is safe is patients with high perioperative risk and comorbid medical conditions, 2002

The Rotary International Ambassadorial Scholarship, 1999

Dipak Kothari Gold Medal & the First “1st” Rank: in the M.CH. (Urology) Examination conducted at the Bombay University, August, 1998

Sethna Scholarship: Traveling scholarship and grant, February, 1998

The Rotary International Ambassadorial Scholarship, January, 1998

JN Tata Scholarship: Traveling scholarship and grant, January, 1998

BD Bangur Scholarship: Traveling scholarship and grant, January, 1998

K.C. Mahindra Scholarship: Traveling scholarship and grant, January, 1998

Ranked Third in University of Bombay: In Postgraduate Examination in General Surgery for M.S. Degree, June 1995

Ranked Third in the All India Competitive Entrance Examination: (National Level) for
Admission into Subspecialty Courses, January 1995

The Dr. Ganesh Ramchandra Washikar Shastra Vidya Scholarship: University of Poona Scholarship (MBBS/Medical School), June 1991

Late Shri Gopal Balkrishna Chitale Prize: University of Poona Scholarship (MBBS/Medical School) 2nd MBBS, June 1991

Late Shri Gopal Balkrishna Chitale Prize: University of Poona Scholarship (MBBS/Medical School) 2nd MBBS, January, 1991

Late Dr. Mukund Limaye Scholarship: University of Poona Scholarship, January 1990

Late Shri Gopal Balkrishna Chitale Prize: University of Poona Scholarship (MBBS/Medical School) 1st MBBS, January 1990

Padmashri Vithalrao Vikhe Patil Scholarship for standing first in 3rd MBBS: University of Poona Scholarship (MBBS/Medical School), January 1990

Padmashri Vithalrao Vikhe Patil Scholarship for standing first in 2nd MBBS: University of Poona Scholarship (MBBS/Medical School), January 1989

Late Dr. VS Sovani Medical Prize: University of Poona Scholarship (MBBS/Medical School), January, 1988

Late Mrudula Mangesh Naik Prize: University of Poona Scholarship (MBBS/Medical School), January, 1988

Late Dr. MJ Sirsikar Scholarship: University of Poona Scholarship (MBBS/Medical School), January, 1987

Padmashri Vithalrao Vikhe Patil Scholarship for standing first in 1st MBBS: University of Poona Scholarship (MBBS/Medical School), January 1987

The Dr. RH Bhadkamkar Memorial Pathology Prize: University of Poona Scholarship (MBBS/Medical School), January, 1986

25. Post-Doctoral Fellowships:

26. **Other Professional Activities:**

1. Role of gracilis sling in anal incontinence, Annual Conference, Maharashtra Chapter of Association of Surgeons of India, Masicon, IN (Co-Presenter). Jan, 1993

2. Complications of laparoscopic cholecystectomy, Masicon, IN (Co-Presenter). April, 1993


5. Xanthogranulomatour pyelonephritis: A 10 year experience, Annual Conference, Urology Society of India, IN (Co-Presenter), Jan, 1997

6. The role of digital rectal examination in the evaluation of local recurrence after radical prostatectomy, Annual Meeting, American Urological Association, Dallas, TX (Co-Presenter). June, 1999

7. Continent urinary reconstruction versus ileal conduit: A contemporary single institution comparison of morbidity, Annual Meeting, American Urological Association, Dallas, TX (Co-Presenter). June, 1999


12. The role of idiopathic hypercalciuria in a subgroup of dysfunctional voiding syndromes of childhood. Southeastern Section of the American Urological Association Meeting, Orlando, FL (Co-Presenter). March, 2000


20. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. Southeastern Section of the American Urological Association Meeting, Naples, FL (Co-Presenter). Feb, 2002

21. Laparoscopic versus hand-assisted radical nephrectomy in the high-risk patient population, Southeastern Section of the American Urological Association Annual Meeting, Naples, FL (Co-Presenter). Feb, 2002


23. Orthotopic neobladder following radical cystectomy is safe in patients with high perioperative risk and comorbid medical conditions. Southeastern Section of the American Urological Association Meeting, Naples, FL (Co-Presenter). Feb 2002


27. Urinary Diversions after Radical Cystectomy, Seminar Series, Urology, Rajkot Urology Society, Rajkot, IN (Invited Speaker). Nov, 2002

28. Urologic Oncology Update, Seminar Urology, Seth GS Medical College and KEM Hospital, Mumbai, IN (Invited Speaker). Dec, 2002

29. Interesting cases in Uro-oncology, KEM Hospital, Mumbai, IN (Invited Speaker). Nov, 2003


31. Renal Cell Carcinoma (RCC) with Renal Vein/Inferior Vena Cava (IVC) Thrombus (T3b/c): Clinicopathologic Features and Outcomes, 4th Annual SUO Meeting, National Institutes of Health, Bethesda, MD (Co-Presenter). Dec, 2003

32. Optical Spectroscopy in Differentiating Benign and Malignant Renal Tissues: A Potentially Useful Modality, 4th Annual SUO Meeting, National Institutes of Health, Bethesda, MD (Sole Presenter). Dec, 2003


34. Optical Spectroscopy in Differentiating Benign and Malignant Renal Tissues: A Potentially Useful Modality, AUA Annual Meeting, San Francisco, CA (Sole Presenter). May, 2004

36. Optical Spectroscopy for Guiding Thermotherapies of Tumors, 2004 Biomedical Optics Conference, OSA, Miami, FL (Co-Presenter). Oct, 2004

37. Optical Spectroscopy in Differentiating Benign and Malignant Renal Tissues: A Potentially Useful Modality, Southeast Section AUA Meeting, Charleston, SC (Co-Presenter). March, 2005


39. Assessing Gender Differences in Pathologic Characteristics and Disease-Specific Outcomes in Radical Cystectomy, AUA Annual Meeting, San Antonio, TX (Sole Presenter). May, 2005

40. Optical Spectroscopy: Immediate modality can differentiate malignant, benign and ablated renal tissue, World Congress in Endourology, Amsterdam, NL (Co-Presenter). Sept, 2005

41. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder, Annual AUA Meeting, AUA, Atlanta, GA (Co-Presenter). May, 2006


44. Current age – and race-adjusted PSA threshold values delay diagnosis of high grade prostate cancer, Annual Meeting, Urology, Kimbrough Urologic Meeting, Houston, TX (Co-Presenter). Jan, 2007

45. The Management of BPH, How to Decide When to use Prazosin or Tamsulosin or Finasteride and How to Deal with the Effect that Finasteride has on the PSA, Annual Family Practice Review Course, San Antonio, TX (Sole Presenter). March, 2007


50. Radical Cystectomy (surgical techniques open vs robotics), Conference, UroOncoogy, UTHSCSA, San Antonio, TX (Sole Presenter). July, 2008
51. NAD(P)H oxidase subunit p22phox mediates hypoxia-inducible factor-2α and is over-expressed in human renal cell carcinoma, Annual Meeting, American Society of Nephrology, Philadelphia, PA (Co-Presenter). Nov, 2008

52. NAD(P)H oxidase subunit p22phox mediates hypoxia-inducible factor-2α transcriptional activity and is over-expressed in human renal cell carcinoma, Cell Growth, Cell Proliferation, Apoptosis, and Neoplasia, ASN, Philadelphia, PA (Sole Presenter). Nov, 2008


54. NAD (P)H oxidase subunit p22phox mediates hypoxia-inducible factor-2α transcriptional activity and is over-expressed in human renal cell carcinoma, SUO Annual Meeting, NIH, AUA, Baltimore, MA (Sole Presenter). Dec, 2008


56. Robotics in Urologic Oncology – Keep an Eye on the Future but Don’t Forget the Past, Annual USICON, Urology Society of India, USICON, Indore, IN (Sole Presenter). Jan, 2009

57. Risk Based Approach for Prostate Cancer, Baptist Health System Cancer Conference, Baptist Health System, Baptist Health System, San Antonio, TX (Invited Speaker). Feb, 2009

58. Prostate-Specific Antigen Stability Confirmed after Long-Term Storage of Serum at -86 Degrees Celsius, 88th Annual Meeting, South Central Section, American Urological Association, Scottsdale, AZ (Co-Presenter). Oct, 2009


60. Robotic Assisted Laparoscopic Adrenalectomy, 88th Annual Meeting, South Central Section, American Urological Association, Scottsdale, AZ (Co-Presenter). Oct, 2009

61. Diagnosis and Management of Bladder Cancer, ACLI Annual Conference, ACLI, San Antonio, TX (Invited Speaker). Feb, 2010

62. The role of robotics in urologic oncology, Grand Rounds, KDAH Hospital, Mumbai, IN (Invited Speaker). Feb, 2010

63. Risk based approach to prostate cancer detection, Evidence Based Medicine Meeting – Genitourinary Oncology, Tata Memorial Cancer Center, Mumbai, IN (Invited Speaker). Feb, 2010

64. Is open prostatectomy on its way out for prostate cancer? Evidence Based Medicine Meeting – Genitourinary Oncology, Tata Memorial Cancer Center, Mumbai, IN (Invited Speaker). Feb, 2010

65. Challenging Cases in Urologic Oncology, Evidence Based Medicine Meeting – Genitourinary Oncology, Tata Memorial Cancer Center, Mumbai, IN (Invited Speaker). Feb, 2010

66. Impact of surgical approaches on outcomes of renal cancer, Evidence Based Medicine Meeting – Genitourinary Oncology, Tata Memorial Cancer Center, Mumbai, IN (Invited Speaker). Feb, 2010
67. Early Cystectomy for T1G3 bladder cancer, Evidence Based Medicine Meeting – Genitourinary Oncology, Tata Memorial Cancer Center, Mumbai, IN (Invited Speaker). Feb, 2010

68. Chemoprevention for Prostate Cancer, St. Gallen Cancer Prevention Annual Conference, St Gallen, SZ (Invited Speaker). March, 2010

69. Screening for Prostate Cancer, 75th National Congress of Urology, Spanish Association of Urology, Bilbao, Spain (Invited Speaker). June, 2010

70. Chemoprevention for Prostate Cancer, 75th National Congress of Urology, Spanish Association of Urology, Bilbao, Spain (Invited Speaker). June, 2010

71. Testicular Cancer, Grand Rounds Urologic Oncology, Department of Urology, UTHSCSA, San Antonio, TX (Sole Presenter). Sept, 2010


73. Not to Screen for Prostate Cancer. Annual Kimbrough Meeting, Seattle, WA (Invited Speaker). Jan, 2011

74. Role of Robotic Radical Cystectomy in Bladder Cancer, Annual Kimbrough Meeting, Seattle, WA (Invited Speaker). Jan, 2011

75. Robotic Surgeons and other challenges with emerging technology in health care. UTPA Bioethics Conference, UTPA, Edinburg, TX (Invited Speaker). March, 2011


81. The role of biomarkers in the setting of clamp induced ischemia of human kidneys – Results from a prospective clinical study, NIDDK ASSESS AKI Meeting, NIDDK, NIDDK, San Francisco, CA (Invited Speaker). Sept, 2011

82. The response of human kidney to renal ischemia – Results from a prospective clinical study, NIDDK KUH Council Meeting, KUH, NIDDK, Bethesda, MD (Invited Speaker). Sept, 2011


89. Open versus Robotic Radical Cystectomy – Results from a Prospective Randomized Trial, Society of Urologic Oncology Annual Meeting, SUO, Bethesda, MD (Co-Presenter). Dec, 2011

90. The role of biomarkers in the setting of clamp induced ischemia of human kidneys – Results from a prospective clinical study, Society of Urologic Oncology Annual Meeting, SUO, Bethesda, MD (Co- Presenter). Dec, 2011

91. A Prospective Trial Assessing the Effects of Clamp Ischemia during Partial Nephrectomy on Renal Function, Structure, and Biomarkers, Society of Urologic Oncology Annual Meeting, SUO, Bethesda, MD (Co-Presenter). Dec, 2011

92. Open versus Robotic Radical Cystectomy – Results from a Prospective Randomized Trial, GU ASCO, San Francisco, CA, (Co-Presenter). Feb, 2012

93. The response of human kidney to renal ischemia – Results from a prospective clinical study, GU ASCO, San Francisco, CA (Sole Presenter). Feb, 2012

94. The role of biomarkers in the setting of clamp induced ischemia of human kidneys – Results from a prospective clinical study, GU ASCO, San Francisco, CA (Sole Presenter). Feb, 2012